In the context of breast cancer, the American Society of Clinical Oncology/College of American Pathologists noted that as many as 20 % of HER2 tests performed may be inaccurate [34], which may also influence studies attempting to determine the frequency of HER2-positive gastric cancer. The gene discussed is ERBB2; the disease is breast cancer.